Interindividual variation of serum haloperidol concentrations in Japanese patients - Clinical considerations on steady-state serum level-dose ratios

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 2, 2003, Pages 97-101

  Yukawa, E ^a   Ichimaru, R ^b   Maki, T ^b   Matsunaga, K ^b   Anai, M ^b   Yukawa, M ^c   Higuchi, S ^d   Goto, Y ^c  

^a DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^b CRC Inc   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Antiepileptic drug; Antiparkinsonian drug; CYP2D6 substrate; Drug interaction; Haloperidol; Level dose ratio

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; BIPERIDEN; BROMOCRIPTINE; CARBAMAZEPINE; CLOMIPRAMINE; CYTOCHROME P450 2D6; HALOPERIDOL; LEVOMEPROMAZINE; MAZATICOL; PERPHENAZINE; PHENOBARBITAL; PHENYTOIN; THIORIDAZINE; TRIHEXYPHENIDYL;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; STEADY STATE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HALOPERIDOL; HUMANS; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0038670227     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00460.x     Document Type: Article

References (14)

1. Ulrich S, Wurthmann C, Brosz M, Meyer FP. (1998) The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clinical Pharmacokinetics, 34, 227-263.
2. Froemming JS, Francis Lam YW, Jann MW, Davis CM. (1989) Pharmacokinetics of haloperidol. Clinical Pharmacokinetics, 17, 396-423.
3. Hirokane G, Someya T, Takahashi S, Morita S, Shimoda K. (1999) Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. Therapeutic Drug Monitoring, 21, 82-86.
4. Kudo S, Ishizaki T. (1999) Pharmacokinetics of haloperidol: an update. Clinical Pharmacokinetics, 37, 435-456.
5. Kamisada M, Oguchi E, Yagi G. (1988) Basic evaluation of enzyme immunoassay for haloperidol level and its clinical application. Journal of Clinical Therapeutics and Medicines, 4, 639-645.
6. ZumBrunnen TL, Jann MW. (1998) Drug interactions with antipsychotic agents: incidence and therapeutic implications. CNS Drugs, 9, 381-401.
7. Fang J, Baker GB, Silverstone PH, Coutts RT. (1996) Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cellular and Molecular Neurobiology, 17, 227-233.
8. Pan LP, Wijnant P, De Vriendt C, Rosseel MT, Belpaire FM. (1997) Characterization of the cytochrome P-450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. British Journal of Clinical Pharmacology, 44, 557-564.
9. Spina E, Pisani F, Perucca E. (1996) Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clinical Pharmacokinetics, 31, 198-214.
10. Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, Burch NR, Bowden CL. (1985) Effects of carbamazepine on plasma haloperidol levels. Journal of Clinical Psychopharmacology, 5, 106-109.
11. Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI. (1986) Does carbamazepine induced reduction of plasma haloperidpol levels worsen psychotic symptoms? American Journal of Psychiatry, 143, 650-651.
12. Kidron R, Averbuch I, Klein E, Belmaker R. (1985) Carbamazepine induced reduction in blood levels of haloperidol in chronic schizophrenia. Biological Psychiatry, 20, 199-228.
13. Linnoila M, Viukari M, Vaisanen K, Auvinen J. (1980) Effect of anticonvulsants on plasma haloperidol and thioridazine levels. American Journal of Psychiatry, 137, 819-821.
14. Anderson GA. (1998) A mechanistic approach to antiepileptic drug interactions. Annals of Pharmacotherapy, 32, 554-563.